RU2014142680A3 - - Google Patents

Download PDF

Info

Publication number
RU2014142680A3
RU2014142680A3 RU2014142680A RU2014142680A RU2014142680A3 RU 2014142680 A3 RU2014142680 A3 RU 2014142680A3 RU 2014142680 A RU2014142680 A RU 2014142680A RU 2014142680 A RU2014142680 A RU 2014142680A RU 2014142680 A3 RU2014142680 A3 RU 2014142680A3
Authority
RU
Russia
Application number
RU2014142680A
Other languages
Russian (ru)
Other versions
RU2014142680A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39820887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2014142680(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2014142680A publication Critical patent/RU2014142680A/ru
Publication of RU2014142680A3 publication Critical patent/RU2014142680A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2014142680A 2007-06-25 2014-10-22 Способ улучшения функциональных свойств антитела или его антигенсвязывающего фрагмента RU2014142680A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93711207P 2007-06-25 2007-06-25
US60/937,112 2007-06-25
US6905608P 2008-03-12 2008-03-12
US61/069,056 2008-03-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2010102065/10A Division RU2540150C2 (ru) 2007-06-25 2008-06-25 Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами

Publications (2)

Publication Number Publication Date
RU2014142680A RU2014142680A (ru) 2016-05-20
RU2014142680A3 true RU2014142680A3 (enExample) 2018-05-28

Family

ID=39820887

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2010102065/10A RU2540150C2 (ru) 2007-06-25 2008-06-25 Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами
RU2014142680A RU2014142680A (ru) 2007-06-25 2014-10-22 Способ улучшения функциональных свойств антитела или его антигенсвязывающего фрагмента
RU2019118109A RU2019118109A (ru) 2007-06-25 2019-06-11 Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2010102065/10A RU2540150C2 (ru) 2007-06-25 2008-06-25 Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2019118109A RU2019118109A (ru) 2007-06-25 2019-06-11 Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами

Country Status (20)

Country Link
US (2) US20090074780A1 (enExample)
EP (1) EP2158315B1 (enExample)
JP (5) JP5611820B2 (enExample)
KR (1) KR101573086B1 (enExample)
CN (6) CN103435696B (enExample)
AU (1) AU2008267734B9 (enExample)
BR (1) BRPI0813645A2 (enExample)
CA (1) CA2689941C (enExample)
DK (1) DK2158315T3 (enExample)
ES (1) ES2566737T3 (enExample)
HR (1) HRP20160730T1 (enExample)
HU (1) HUE027507T2 (enExample)
IL (1) IL202360A (enExample)
MX (1) MX2009013328A (enExample)
NZ (2) NZ601946A (enExample)
PL (1) PL2158315T3 (enExample)
RU (3) RU2540150C2 (enExample)
SI (1) SI2158315T1 (enExample)
WO (1) WO2009000099A2 (enExample)
ZA (1) ZA200908384B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
CN101222758B (zh) 2007-01-08 2011-10-26 中兴通讯股份有限公司 一种在高速分组数据网传递1x寻呼被拒绝的方法
RU2009137582A (ru) * 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
BRPI0813645A2 (pt) * 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
KR101834797B1 (ko) 2008-06-25 2018-03-07 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
MX345039B (es) 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
PT2307454T (pt) 2008-06-25 2017-04-26 Esbatech Alcon Biomed Res Unit Anticorpos estáveis e solúveis que inibem o vegf
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
JP5988580B2 (ja) 2008-06-30 2016-09-07 エスバテック − ア ノバルティス カンパニー エルエルシー 機能性ポリペプチド
CA2755133A1 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
TW201129379A (en) 2009-11-20 2011-09-01 Amgen Inc Anti-Orai1 antigen binding proteins and uses thereof
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2624868B1 (en) 2010-10-08 2018-09-26 City of Hope A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
AU2016277637B2 (en) * 2010-10-22 2018-11-08 Novartis Ag Stable and soluble antibodies
AU2013203189B2 (en) * 2010-10-22 2014-12-11 Novartis Ag Stable and soluble antibodies
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
WO2013055404A1 (en) * 2011-10-10 2013-04-18 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
TWI577696B (zh) * 2011-10-20 2017-04-11 Ｅｓｂａ科技 諾華有限責任公司 穩定的多重抗原結合抗體
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
AU2013259276B2 (en) 2012-05-10 2018-03-22 Bioatla Llc Multi-specific monoclonal antibodies
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
KR102286053B1 (ko) 2013-06-26 2021-08-04 누맙 세러퓨틱스 아게 신규한 항체 기본구조
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
PT3248986T (pt) * 2014-05-16 2022-04-05 Ablynx Nv Domínios variáveis de imunoglobulina
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
SG11201706014PA (en) 2015-02-05 2017-08-30 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2017049004A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
KR20180111870A (ko) 2016-02-25 2018-10-11 셀 메디카 스위처란트 아게 Pd-l1에 대한 결합 성분
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
MX2019005552A (es) 2016-11-14 2019-08-12 Amgen Inc Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
KR102698752B1 (ko) * 2017-03-20 2024-08-26 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
KR20200132938A (ko) 2018-03-15 2020-11-25 추가이 세이야쿠 가부시키가이샤 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
KR20210009421A (ko) 2018-06-14 2021-01-26 바이오아트라, 엘엘씨 다중 특이적 항체 구조체
CN113260627B (zh) * 2019-01-03 2025-01-03 美国安进公司 工程化单克隆抗体以改善稳定性和生产滴度
TWI879770B (zh) 2019-05-30 2025-04-11 美商安進公司 工程改造鉸鏈區以驅動抗體二聚化
CA3143524A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
EP3767628B1 (de) * 2019-07-18 2024-03-27 Bayer Aktiengesellschaft Selektion von antikörpern / antikörperfragmenten
JP7677964B2 (ja) 2019-11-08 2025-05-15 アムジエン・インコーポレーテツド ヘテロＩｇＧ分子の対合のための電荷対変異の操作
US20230047631A1 (en) 2019-11-19 2023-02-16 Amgen Inc. Novel multispecific antibody format
US11926672B2 (en) 2019-12-20 2024-03-12 Amgen Inc. Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
EP4200338A1 (en) 2020-08-20 2023-06-28 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
CA3197047A1 (en) 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
TW202233663A (zh) 2020-11-10 2022-09-01 美商安進公司 多特異性抗原結合結構域之新穎的連接子
CA3208905A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
JP2024509910A (ja) 2021-03-09 2024-03-05 シーディアール－ライフ・アクチェンゲゼルシャフト Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質
MX2023012324A (es) 2021-04-20 2023-10-30 Amgen Inc Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
CA3240046A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
WO2024251780A1 (en) * 2023-06-05 2024-12-12 Sanofi Predicting properties of single variable domains using machine-learning models
WO2025210181A1 (en) 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
US20250333514A1 (en) 2024-04-11 2025-10-30 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted prame peptide

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1197800A (en) * 1983-05-02 1985-12-10 William O. Weigle Immune modulator peptides
DK0531472T3 (da) 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69427974T2 (de) * 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
JP2002522511A (ja) 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6602977B1 (en) 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
ES2225269T3 (es) 1999-12-28 2005-03-16 Esbatech Ag Intracuerpos con esqueleto definido que es estable en un ambiente reductor y aplicaciones de los mismos.
EP1294770B1 (en) * 2000-05-10 2011-12-07 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
AR035352A1 (es) 2000-10-13 2004-05-12 Biogen Inc Anticuerpos anti-lt-beta-r humanizados
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
PT1390535E (pt) 2001-04-26 2010-10-04 Amgen Mountain View Inc Bibliotecas combinatórias de domínios monoméricos
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
EP1401470A4 (en) * 2001-06-04 2005-05-25 Curagen Corp NEW ANTIBODIES BINDING TO ANTIGENIC POLYPEPTIDES, THE ANTIGENE ENCODING NUCLEIC ACIDS AND METHOD FOR THEIR USE
JP4355571B2 (ja) * 2001-07-19 2009-11-04 ウニベルジテート チューリッヒ ヒト可変ドメインの改変
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
JP4246069B2 (ja) 2001-12-28 2009-04-02 協和発酵キリン株式会社 関節炎の治療薬
US6905608B2 (en) 2002-01-22 2005-06-14 Exergy Technologies Corporation Advanced electrodeionization for fluid recycling
CN103739706B (zh) * 2002-05-22 2015-11-18 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN1678625A (zh) 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
KR101115797B1 (ko) 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법
PT1572744E (pt) * 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
AU2004205684A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
CN1798767B (zh) * 2003-04-10 2011-02-16 晶面生物技术公司 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EP1644039B1 (en) 2003-06-19 2014-10-01 Genentech, Inc. Compositions and methods for treating coagulation related disorders
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
AR047729A1 (es) * 2003-11-28 2006-02-15 Astrazeneca Ab Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
JP2008500064A (ja) 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファウンデーション 可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用
HRP20110320T1 (hr) 2004-05-27 2011-05-31 Crucell Holland B.V. Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba
GB0416651D0 (en) * 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
ES2558338T3 (es) 2005-03-25 2016-02-03 National Research Council Of Canada Método para aislamiento de polipéptidos solubles
EP1889908A4 (en) 2005-06-03 2012-04-25 Mochida Pharm Co Ltd PROTEIN FUSED WITH ANTI-CD14 ANTIBODY
ES2424042T3 (es) 2005-06-07 2013-09-26 Esbatech - A Novartis Company Llc Anticuerpos estables y solubles que inhiben TNF±
NZ564567A (en) 2005-07-05 2010-09-30 Glaxo Group Ltd Humanised antibodies specific for neurite outgrowth inhibitor-A and pharmaceutical uses thereof
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007031875A2 (en) 2005-08-26 2007-03-22 Glycart Biotechnology Ag Modified antigen binding molecules with altered cell signaling activity
EP1957541A2 (en) * 2005-11-21 2008-08-20 Laboratoires Serono SA Compositions and methods of producing hybrid antigen binding molecules and uses thereof
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
DK1963368T6 (da) * 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP3093026B1 (en) * 2006-07-10 2020-07-01 ESBATech, an Alcon Biomedical Research Unit LLC Scfv antibodies which pass epithelial and/or endothelial layers
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CN101210241A (zh) * 2006-12-27 2008-07-02 陕西超英生物科技有限公司 一种噬菌体基因工程抗体库基因组装的方法
RU2009137582A (ru) 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
BRPI0813645A2 (pt) * 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR

Also Published As

Publication number Publication date
JP2015007104A (ja) 2015-01-15
JP5611820B2 (ja) 2014-10-22
JP2017186338A (ja) 2017-10-12
CN103435696B (zh) 2016-10-12
EP2158315B1 (en) 2016-03-23
HRP20160730T1 (hr) 2016-07-15
RU2010102065A (ru) 2011-07-27
CN106366192A (zh) 2017-02-01
ZA200908384B (en) 2011-02-23
BRPI0813645A2 (pt) 2014-12-30
CN103435696A (zh) 2013-12-11
CN102838673A (zh) 2012-12-26
EP2158315A2 (en) 2010-03-03
ES2566737T3 (es) 2016-04-15
KR101573086B1 (ko) 2015-11-30
CN102838673B (zh) 2016-05-11
CN101849001B (zh) 2014-07-16
CN111253484A (zh) 2020-06-09
JP2019141091A (ja) 2019-08-29
AU2008267734B2 (en) 2014-07-24
DK2158315T3 (en) 2016-06-06
AU2008267734B9 (en) 2014-09-11
JP2010531145A (ja) 2010-09-24
IL202360A (en) 2015-07-30
SI2158315T1 (sl) 2016-05-31
RU2019118109A (ru) 2020-12-11
NZ581468A (en) 2012-09-28
RU2014142680A (ru) 2016-05-20
CN106366192B (zh) 2020-03-27
US20090074780A1 (en) 2009-03-19
WO2009000099A3 (en) 2009-04-09
KR20100028575A (ko) 2010-03-12
CN101849001A (zh) 2010-09-29
RU2540150C2 (ru) 2015-02-10
IL202360A0 (en) 2011-08-01
JP6129797B2 (ja) 2017-05-17
HK1137483A1 (zh) 2010-07-30
NZ601946A (en) 2013-12-20
AU2008267734A1 (en) 2008-12-31
CA2689941A1 (en) 2008-12-31
JP2021119782A (ja) 2021-08-19
HUE027507T2 (en) 2016-10-28
WO2009000099A2 (en) 2008-12-31
CN105017427A (zh) 2015-11-04
US20190002551A1 (en) 2019-01-03
CA2689941C (en) 2019-10-29
MX2009013328A (es) 2010-06-02
PL2158315T3 (pl) 2016-10-31

Similar Documents

Publication Publication Date Title
RU2014142680A3 (enExample)
CN300729579S (zh) 塑料包装袋
CN300728654S (zh) 包(bay quil ted-377)
CN300885043S (zh) 人体静电消除器(cm-3c)
CN300852652S (zh) 折叠式婴儿车用车轮保持件
CN300840557S (zh) 旅行壶
CN300726214S (zh) 布(27)
CN300830633S (zh) 电冰箱(对开三门2007-1)
CN300814070S (zh) 女袜(2)
CN300781898S (zh) 摄像机(室内高速球)
CN300726221S (zh) 面料(欧根沙)
CN300776746S (zh) 灯饰(北极熊)
CN300772209S (zh) 仿古屏风包装盒
CN300769705S (zh) 连接器端子
CN300750945S (zh) 袜标(qy003)
CN300750845S (zh) 笔(带激光和u盘)
CN300747653S (zh) 轮胎(六)
CN300740191S (zh) T恤衫(062594)
CN300730949S (zh) 牙线棒
CN300730918S (zh) 汽车灯具(xhj-004)
CN300730827S (zh) 蜡烛(152)
CN300730807S (zh) 蜡烛(210)
CN300730714S (zh) 烛台(221)
CN300730603S (zh) 砖(树皮砖)
CN300726210S (zh) 布(37)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190715